Christopher I. Wright
CIK: 0001838503
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jun 12, 2026ALKS
Alkermes plc.
Sale(S)Direct2K shares at avg. $45.10$90K - May 21, 2026ALKS
Alkermes plc.
Tax Payment(F)Direct1.5K shares at avg. $36.95$55K - May 21, 2026ALKS
Alkermes plc.
Exercise(M)Direct6.1K shares- - May 20, 2026ALKS
Alkermes plc.
Award(A)DirectRestricted Stock Unit Award
5.4K shares- - May 20, 2026ALKS
Alkermes plc.
Award(A)DirectNon Qualified Stock Option (Right to Buy)
11.5K shares- - Jun 8, 2025ALKS
Alkermes plc.
Exercise(M)Direct3.3K shares- - Jun 8, 2025ALKS
Alkermes plc.
Tax Payment(F)Direct793 shares at avg. $31.71$25K - May 31, 2025ALKS
Alkermes plc.
Tax Payment(F)Direct1.9K shares at avg. $30.61$59K - May 31, 2025ALKS
Alkermes plc.
Exercise(M)Direct8K shares- - May 21, 2025ALKS
Alkermes plc.
Award(A)DirectNon Qualified Stock Option (Right to Buy)
13.5K shares- - May 21, 2025ALKS
Alkermes plc.
Award(A)DirectRestricted Stock Unit Award
6.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 12, 2026 |  ALKS Alkermes plc. | Sale(S) | 2,000 | $45.10 | $90,200 | Direct |
| May 21, 2026 | ALKS Alkermes plc. | Tax Payment(F) | 1,475 | $36.95 | $54,501 | Direct |
| May 21, 2026 | ALKS Alkermes plc. | Exercise(M) | 6,142 | - | $0 | Direct |
| May 20, 2026 | ALKS Alkermes plc. | Award(A) Restricted Stock Unit Award | 5,409 | - | - | Direct |
| May 20, 2026 | ALKS Alkermes plc. | Award(A) Non Qualified Stock Option (Right to Buy) | 11,538 | - | - | Direct |
| Jun 8, 2025 | ALKS Alkermes plc. | Exercise(M) | 3,301 | - | - | Direct |
| Jun 8, 2025 | ALKS Alkermes plc. | Tax Payment(F) | 793 | $31.71 | $25,146 | Direct |
| May 31, 2025 | ALKS Alkermes plc. | Tax Payment(F) | 1,924 | $30.61 | $58,894 | Direct |
| May 31, 2025 | ALKS Alkermes plc. | Exercise(M) | 8,013 | - | - | Direct |
| May 21, 2025 | ALKS Alkermes plc. | Award(A) Non Qualified Stock Option (Right to Buy) | 13,474 | - | - | Direct |
| May 21, 2025 | ALKS Alkermes plc. | Award(A) Restricted Stock Unit Award | 6,142 | - | - | Direct |
1-11 of 11 transactions
About Wright Christopher I
Wright Christopher I (SEC CIK 0001838503) files insider reports with the SEC as Director of Alkermes plc. (ALKS) and Chief Medical Officer of Wave Life Sciences Ltd. (WVE).
Signal8 holds 6 ownership filings by Wright Christopher I (1 Form 3, 5 Form 4), filed between May 23, 2025 and Jun 12, 2026. Those filings report 11 transactions, from May 21, 2025 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Wright Christopher I's filings is in DUBLIN.
Recent filings by Wright Christopher I
- Jun 12, 2026: Open-market sale of ALKS shares (Form 4, code S).
- May 21, 2026: Tax withholding of ALKS shares (Form 4, code F).
- May 21, 2026: Option exercise of ALKS shares (Form 4, code M).
- May 20, 2026: Grants or awards of ALKS derivative securities (2 lines, Form 4, code A).
- Jun 8, 2025: Option exercise of ALKS shares (Form 4, code M).
Other insiders filing for Alkermes plc. (ALKS)
- Gaffin David Joseph, EVP, CLO, Alkermes, Inc.
- Reed Joshua, SVP, Chief Financial Officer
- Whitaker Anne Clem, Director
- Hopkinson Craig C., EVP R&D, Chief Medical Officer
- Nichols Christian Todd, SVP, Chief Commercial Officer
- Jackson Blair Curtis, President & CEO, Alkermes plc